Galantamine357-70-0
357-70-0
pharmaceutical grade
99%
1
Ipure
25kg/Cardboard Drum
2026-03-28
pharmaceutical intermediates,chemical
-
Product Description
-
Seller Information
-
DescriptionECHEMI Editorial ReferenceGalanthamine is a potent acetylcholinesterase (AChE) inhibitor with an IC50 of 500 nM.
Solid
Galanthamine is a benzazepine alkaloid isolated from certain species of daffodils. It has a role as an antidote to curare poisoning, an EC 3.1.1.7 (acetylcholinesterase) inhibitor, a cholinergic drug, an EC 3.1.1.8 (cholinesterase) inhibitor and a plant metabolite. It is an organic heterotetracyclic compound, a tertiary amino compound, a benzazepine alkaloid and a benzazepine alkaloid fundamental parent. It is a conjugate base of a galanthamine(1+).|Galantamine is a tertiary alkaloid and reversible, competitive inhibitor of the acetylcholinesterase (AChE) enzyme, which is a widely studied therapeutic target used in the treatment of Alzheimer's disease. First characterized in the early 1950s, galantamine is a tertiary alkaloid that was extracted from botanical sources, such as Galanthus nivalis. Galantamine was first studied in paralytic and neuropathic conditions, such as myopathies and postpolio paralytic conditions, and for reversal of neuromuscular blockade. Following the discovery of its AChE-inhibiting properties, the cognitive effects of galantamine were studied in a wide variety of psychiatric disorders such as mild cognitive impairment, cognitive impairment in schizophrenia and bipolar disorder, and autism; however, re-development of the drug for Alzheimer’s disease did not commence until the early 1990s due to difficulties in extraction and synthesis. Galantamine blocks the breakdown of acetylcholine in the synaptic cleft, thereby increasing acetylcholine neurotransmission. It also acts as an allosteric modulator of the nicotinic receptor, giving its dual mechanism of action clinical significance. The drug was approved by the FDA in 2001 for the treatment of mild to moderate dementia of the Alzheimer's type. As Alzheimer's disease is a progressive neurodegenerative disorder, galantamine is not known to alter the course of the underlying dementing process. Galantamine works to block the enzyme responsible for the breakdown of acetylcholine in the synaptic cleft, thereby enhancing cholinergic neuron function and signalling. Under this hypothesized mechanism of action, the therapeutic effects of galantamine may decrease as the disease progression advances and fewer cholinergic neurons remain functionally intact. It is therefore not considered to be a disease-modifying drug. Galantamine is marketed under the brand name Razadyne, and is available as oral immediate- and extended-release tablets and solution.|Galantamine is a Cholinesterase Inhibitor. The mechanism of action of galantamine is as a Cholinesterase Inhibitor.|Galantamine is an oral acetylcholinesterase inhibitor used for therapy of Alzheimer disease. Galantamine is associated with a minimal rate of serum enzyme elevations during therapy and has not been implicated as a cause of clinically apparent liver injury.|A benzazepine derived from norbelladine. It is found in GALANTHUS and other AMARYLLIDACEAE. It is a cholinesterase inhibitor that has been used to reverse the muscular effects of GALLAMINE TRIETHIODIDE and TUBOCURARINE and has been studied as a treatment for ALZHEIMER DISEASE and other central nervous system disorders.Basic Info-
Product Name:
(-)-Galantamine
Other Name:6H-Benzofuro[3a,3,2-ef][2]benzazepin-6-ol,4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-,(4aS,6R,8aS)-;Galanthamine;6H-Benzofuro[3a,3,2-ef][2]benzazepin-6-ol,4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-;(4aS,6R,8aS)-4a,5,9,10,11,12-Hexahydro-3-methoxy-11-methyl-6H-benzofuro[3a,3,2-ef][2]benzazepin-6-ol;Galantamine;Lycoremine;Jilkon;Galantamin;Lycoremin;6H-Benzofuro[3a,3,2-ef][2]benzazepin-6-ol,4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-,[4aS-(4aα,6β,8aR*)]-;(-)-Galanthamine;NSC 100058;Galantamina;BRN 0093736;(-)-Galantamine;736-79-8;1551-02-6;1008759-59-8
CAS No.:357-70-0
Molecular Formula:C17H21NO3
InChIKeys:InChIKey=ASUTZQLVASHGKV-JDFRZJQESA-N
Molecular Weight:287.35
Exact Mass:287.35
EC Number:1308068-626-2
UNII:0D3Q044KCA
NSC Number:759861
DSSTox ID:DTXSID2045606
Color/Form:Crystals from benzene
ATC Code:N06DA04|N - Nervous system
HScode:2942000000
Categories:
Characteristics-
PSA:
41.93000
XLogP3:1.75
Appearance:Solid
Density:1.3±0.1 g/cm3
Melting Point:126-127 °C
Boiling Point:439.3±45.0 °C at 760 mmHg
Flash Point:219.5±28.7 °C
Refractive Index:1.636
Water Solubility:1.70e+00 g/L
Storage Conditions:-20°C Freezer
Toxicity:LD50 intraperitoneal in mouse: 10mg/kg
Specific rotation:D20 -118.8° (c = 1.378 in ethanol)
Dissociation Constants:pKa = 7.97 (est)
Collision Cross Section:166.9 Ų [M+H]+ [CCS Type: TW, Method: Major Mix IMS/Tof Calibration Kit (Waters)]|168.2 Ų [M+H]+ [CCS Type: DT, Method: single field calibrated]
Experimental Properties:Monoacidic base|White to almost white powder ... sparingly soluble in water /Hydrobromide/
Hazard IdentificationClassification of the substance or mixture
Acute toxicity - Category 3, Oral
Skin irritation, Category 2
Skin sensitization, Category 1
Eye irritation, Category 2
Acute toxicity - Category 3, Inhalation
Specific target organ toxicity â repeated exposure, Category 2
Hazardous to the aquatic environment, short-term (Acute) - Category Acute 1
Hazardous to the aquatic environment, long-term (Chronic) - Category Chronic 1
GHS label elements, including precautionary statements
Pictogram(s)
Signal word Danger
Hazard statement(s) H301+H331 Toxic if swallowed or if inhaled
H315 Causes skin irritation
H317 May cause an allergic skin reaction
H319 Causes serious eye irritation
H373 May cause damage to organs through prolonged or repeated exposure
H410 Very toxic to aquatic life with long lasting effects
Precautionary statement(s) Prevention P264 Wash ... thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P280 Wear protective gloves/protective clothing/eye protection/face protection/hearing protection/...
P261 Avoid breathing dust/fume/gas/mist/vapours/spray.
P272 Contaminated work clothing should not be allowed out of the workplace.
P271 Use only outdoors or in a well-ventilated area.
P260 Do not breathe dust/fume/gas/mist/vapours/spray.
P273 Avoid release to the environment.
Response P301+P316 IF SWALLOWED: Get emergency medical help immediately.
P321 Specific treatment (see ... on this label).
P330 Rinse mouth.
P302+P352 IF ON SKIN: Wash with plenty of water/...
P332+P317 If skin irritation occurs: Get medical help.
P362+P364 Take off contaminated clothing and wash it before reuse.
P333+P317 If skin irritation or rash occurs: Get medical help.
P305+P351+P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P304+P340 IF INHALED: Remove person to fresh air and keep comfortable for breathing.
P316 Get emergency medical help immediately.
P319 Get medical help if you feel unwell.
P391 Collect spillage.
Storage P405 Store locked up.
P403+P233 Store in a well-ventilated place. Keep container tightly closed.
Disposal P501 Dispose of contents/container to an appropriate treatment and disposal facility in accordance with applicable laws and regulations, and product characteristics at time of disposal.
Other hazards which do not result in classification
no data available
Handling and StoragePrecautions for safe handling
Handling in a well ventilated place. Wear suitable protective clothing. Avoid contact with skin and eyes. Avoid formation of dust and aerosols. Use non-sparking tools. Prevent fire caused by electrostatic discharge steam.
Conditions for safe storage, including any incompatibilities
Store the container tightly closed in a dry, cool and well-ventilated place. Store apart from foodstuff containers or incompatible materials.
-
-
Seller Information
-
Business Type:
Trader
-
Main Products:
pharmaceutical intermediates,chemical
-
Location:
Company Office Address: Room 1508, 15/F, Yate Centre Office Tower 2, 625 Nathan Road, Mong Kok, Hong Kong
-
Payment Terms:
TT against copy of documents,D/P,L/C,O/A,100% TT in advance
-
Average lead Time:
10
-
Total Annual Revenue:
$1 million-$2.5 million
-
Total Employees:
11-50
-
Year of Establishment:
2025
-
-
Country Product Purchase Quantity Date Posted Post an enquiry for this product